425.14KMarket Cap0.02P/E (TTM)
0.139High0.076Low16.30KVolume0.076Open0.075Pre Close1.98KTurnover0.48%Turnover RatioLossP/E (Static)3.41MShares14.74652wk High-0.14P/B422.25KFloat Cap0.00252wk Low--Dividend TTM3.38MShs Float4200.000Historical High--Div YieldTTM84.29%Amplitude0.002Historical Low0.121Avg Price1Lot Size
Tracon Pharmaceuticals Stock Forum
TRACON Pharmaceuticals Inc - Announces It Will Wind Down Operations
why is it falling
TRACON Announces Publication in Clinical Cancer Research of Phase 2 Clinical Data for TRC102, a DNA Damage Repair Inhibitor, in Recurrent Glioblastoma Patients
TRACON Pharmaceuticals (NASDAQ: TCON) announced the publication of Phase 2 clinical data on its DNA damage repair inhibitor, TRC102, in recurrent glioblastoma patients.
Published in Clinical Cancer Research, the study evaluated TRC102 combined with Temodar in 19 patients who had progression following ...
No comment yet